Press Releases

Skepticism is (and should be) a vital part of any science; statistics and data science are no exception. Statistician George Box nicely summed it up when he said, “all models are wrong, but some are useful”. Box reminds us that statistical models are just that: models. A simplified representation of the real-world will always have shortcomings. But we shouldn’t forget the last bit of Box’s saying: “some [models] are useful”. Although challenging, carefully constructed statistical models can be extremely useful... read post here.

• Google Maps now predicts how difficult it will be to park near your destination based on the behavior of other users in the area.
• Airbnb uses attributes of its users and available properties to generate personalized search results that lead to higher booking rates.
• twoXAR is predicting new drug candidates outside of the wet lab using biomedical data.

These three accomplishments are all possible today because of machine learning... read post here.

I was about twelve when I found out my grandmother had breast cancer. My parents did a good job of shielding me from the worst of the details, but there is no way to avoid fear that comes from a loved one being diagnosed with cancer. As a kid, there wasn’t much I could do, but my grandmother loves to tell the story of me trying to comfort her by telling her I was going to do research to help cure her cancer. Little did I know at the time that treating cancer is not as simple as taking a pill once a day and that even identifying the right medicine is akin to finding a needle in a haystack.

Over the next seventeen years, as I pursued undergraduate and graduate studies in biology and genetics, I filled in those knowledge gaps, but felt no closer to changing the status quo of breast cancer... read post here.

In September 2016, we announced a collaboration with the Asian Liver Center at Stanford University School of Medicine (the Asian Liver Center). The goal of this collaboration was to identify new drug candidates targeting hepatocellular carcinoma (HCC, the major form of adult liver cancer). Today, we announced a lead candidate, TXR-311, that has shown positive results in cell-based assays. I wanted to share a bit more background on liver cancer and details on why these results are exciting.

HCC is a primary cancer of the liver that tends to... read post here.

Today we announced our collaboration with Santen, a world leader in the development of innovative ophthalmology treatments. Scientists at twoXAR will use our proprietary computational drug discovery platform to discover, screen and prioritize novel drug candidates with potential application in glaucoma. Santen will then develop and commercialize drug candidates arising from the collaboration. This collaboration is an exciting example of how artificial intelligence-driven approaches can move beyond supporting existing hypotheses and lead the discovery of new drugs. Combining twoXAR’s unique capabilities with Santen’s experience in ophthalmic product development and commercialization provides a foundation for rapid discovery and development of new and improved therapeutic candidates... read post here.

We at twoXAR were very honored to be included this week in The AI 100, CBInsight’s list of top private Artificial Intelligence companies. It’s given me a chance to reflect on how we employ AI relative to others in the industry.

Our focus is on drug development — and being one of the few biopharma companies to be included in the list, we use AI in a unique way. Where others may be using AI as the sole ingredient... read post here.

twoXAR CEO, Andrew A. Radin, speaks on Computational Drug Design panel.

twoXAR CEO, Andrew A. Radin, is joined by GSK's John Baldoni, and Nimbus's Mark Ashwell.

Interested in connecting @ BIF? Contact us here.

twoXAR Chief Marketing Officer, Andrew M. Radin, discusses artificial intelligence in drug discovery.

Interested in connecting @ BioNetwork? Contact us here.

twoXAR CEO, Andrew A. Radin, speaks on Innovations Impacting the Healthcare Industry panel.

Interested in connecting @ BIO-Europe? Contact us here.